Regorafenib (Stivarga) in all diseases

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search



Colon cancer

GIST (Gastrointestinal Stromal Tumor)

Hepatocellular carcinoma

Source: Regorafenib (Stivarga) for hepatocellular carcinoma

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
Bruix et al. 2016 (RESORCE) Phase III Placebo Superior OS

Chemotherapy

28-day cycles

References

  1. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36. link to original article contains protocol PubMed